冠心病的精准治疗
陈航炜, 戴秋艳 . 冠心病的精准治疗[J]. 内科理论与实践, 2021 , 16(03) : 212 -216 . DOI: 10.16138/j.1673-6087.2021.03.016
| [1] | Gimbrone MA Jr, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis[J]. Circ Res, 2016, 118(4): 620-636. |
| [2] | Malakar AK, Choudhury D, Halder B, et al. A review on coronary artery disease, its risk factors, and therapeutics[J]. J Cell Physiol, 2019, 234(10): 16812-16823. |
| [3] | Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update[J]. Circulation, 2020, 141(9): e139-e596. |
| [4] | Zhao D, Liu J, Wang M, et al. Epidemiology of cardiovascular disease in China: current features and implications[J]. Nat Rev Cardiol, 2019, 16(4): 203-212. |
| [5] | Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease[J]. Circulation, 2019, 140(11): e596-e646. |
| [6] | Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J, 2020, 41(3): 407-477. |
| [7] | Yusuf S, Joseph P, Dans A, et al. Polypill with or without aspirin in persons without cardiovascular disease[J]. N Engl J Med, 2021, 384(3): 216-228. |
| [8] | Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease[J]. J Am Coll Cardiol, 2016, 68(10): 1082-1115. |
| [9] | Kvasnicka T, Malikova I, Zenahlikova Z, et al. Rivaroxaban - metabolism, pharmacologic properties and drug interactions[J]. Curr Drug Metab, 2017, 18(7): 636-642. |
| [10] | Gurbel PA, Fox KAA, Tantry US, et al. Combination antiplatelet and oral anticoagulant therapy in patients with coronary and peripheral artery disease[J]. Circulation, 2019, 139(18): 2170-2185. |
| [11] | Thomas CD, Johnson JA. Pharmacogenetic factors affecting β-blocker metabolism and response[J]. Expert Opin Drug Metab Toxicol, 2020, 16(10): 953-964. |
| [12] | Lee JS, Chang PY, Zhang Y, et al. Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status[J]. Diabetes Care, 2017, 40(4): 529-537. |
| [13] | 中华医学会心血管病学分会, 中国康复医学会心脏预防与康复专业委员会, 中国老年学和老年医学会心脏专业委员会, 等. 中国心血管病一级预防指南[J]. 中华心血管病杂志, 2020, 48(12): 1000-1038. |
| [14] | Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias[J]. Eur Heart J, 2020, 41(1): 111-188. |
| [15] | Lee SE, Chang HJ, Sung JM, et al. Effects of statins on coronary atherosclerotic plaques[J]. JACC Cardiovasc Imaging, 2018, 11(10): 1475-1484. |
| [16] | Agrawal H, Choy HK, Liu J, et al. Coronary artery disease[J]. Arterioscler Thromb Vasc Biol, 2020, 40(7): e185-e192. |
| [17] | Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy[J]. Lancet, 2016, 388(10059): 2532-2561. |
| [18] | Qamar A, Giugliano RP, Bohula EA, et al. Biomarkers and clinical cardiovascular outcomes with ezetimibe in the IMPROVE-IT trial[J]. Am Coll Cardiol, 2019, 74(8): 1057-1068. |
| [19] | Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients[J]. N Engl J Med, 2017, 376(16): 1527-1539. |
| [20] | Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med, 2018, 379(22): 2097-2107. |
| [21] | Nambi V, Agha A. Inclisiran: a game changer in a changing game?[J]. J Am Coll Cardiol, 2021, 77(9): 1194-1196. |
| [22] | Wright RS, Ray KK, Raal FJ, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis[J]. J Am Coll Cardiol, 2021, 77(9): 1182-1193. |
| [23] | Crea F, Libby P. Acute coronary syndromes[J]. Circulation, 2017, 136(12): 1155-1166. |
| [24] | Xu S, Ni H, Chen H, et al. The interaction between STAT3 and nAChRα1 interferes with nicotine-induced atherosclerosis via Akt/mTOR signaling cascade[J]. Aging (Albany NY), 2019, 11(19): 8120-8138. |
| [25] | Xu S, Chen H, Ni H, et al. Targeting HDAC6 attenuates nicotine-induced macrophage pyroptosis via NF-kB/NLRP3[J]. Atherosclerosis, 2021, 317: 1-9. |
| [26] | Chatterjee M, Rath D, Schlotterbeck J, et al. Regulation of oxidized platelet lipidome: implications for coronary artery disease[J]. Eur Heart J, 2017, 38(25): 1993-2005. |
| [27] | Ridker PM, Everett BM, Thuren T, et al. Antiinflamma-tory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med, 2017, 377(12): 1119-1131. |
| [28] | Hansson GK. Inflammation and atherosclerosis[J]. Circulation, 2017, 136(20): 1875-1877. |
| [29] | Costopoulos C, Timmins LH, Huang Y, et al. Impact of combined plaque structural stress and wall shear stress on coronary plaque progression, regression, and changes in composition[J]. Eur Heart J, 2019, 40(18): 1411-1422. |
| [30] | Patel R, Janoudi A, Vedre A, et al. Plaque rupture and thrombosis are reduced by lowering cholesterol levels and crystallization with ezetimibe and are correlated with fluorodeoxyglucose positron emission tomography[J]. Arterioscler Thromb Vasc Biol, 2011, 31(9): 2007-2014. |
| [31] | Libby P, Pasterkamp G, Crea F, et al. Reassessing the mechanisms of acute coronary syndromes[J]. Circ Res, 2019, 124(1): 150-160. |
| [32] | Jia H, Dai J, Hou J, et al. Effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion (the EROSION study)[J]. Eur Heart J, 2017, 38(11): 792-800. |
| [33] | Gao B, Zhang Z, Qian J, et al. The use of calcium channel blockers in the treatment of coronary spasm and atrioventricular block[J]. Cell Biochem Biophys, 2015, 72(2): 527-531. |
| [34] | Gupta RM, Hadaya J, Trehan A, et al. A genetic variant associated with five vascular diseases is a distal regulator of endothelin-1 gene expression[J]. Cell, 2017, 170(3): 522-533. |
| [35] | Ford TJ, Corcoran D, Padmanabhan S, et al. Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction[J]. Eur Heart J, 2020, 41(34): 3239-3252. |
| [36] | Bairey Merz CN, Pepine CJ, Shimokawa H, et al. Treatment of coronary microvascular dysfunction[J]. Cardiovasc Res, 2020, 116(4): 856-870. |
| [37] | Taqueti VR, Di Carli VMFR. Coronary microvascular disease pathogenic mechanisms and therapeutic options: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2018, 72(21): 2625-2641. |
| [38] | Kaski JC, Crea F, Gersh BJ, et al. Reappraisal of ischemic heart disease[J]. Circulation, 2018, 138(14): 1463-1480. |
| [39] | 中国老年医学学会心血管病分会. 中国多学科微血管疾病诊断与治疗专家共识[J]. 中国循环杂志, 2020, 35(12): 1149-1165. |
| [40] | Suda A, Takahashi J, Hao K, et al. Coronary functional abnormalities in patients with angina and nonobstructive coronary artery disease[J]. J Am Coll Cardiol, 2019, 74(19): 2350-2360. |
| [41] | Tunc E, Eve AA, Madak-Erdogan Z. Coronary microvascular dysfunction and estrogen receptor signaling[J]. Trends Endocrinol Metab, 2020, 31(3): 228-238. |
/
| 〈 |
|
〉 |
